BOSTON, Jan. 24 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. today
announced that its Chief Executive Officer, Thomas J. Bigger, will present an
overview of the Company's strategy and research programs at the Piper Jaffray
17th Annual Healthcare Conference in New York City. Details of the
Date: Wednesday, January 26, 2005
Time: 1:55 p.m. (EST)
Location: The Pierre Hotel; Regency A room
Speaker: Thomas J. Bigger, Chief Executive Officer
Mr. Bigger's presentation will review Paratek's Tetracycline ("TET") and
Multiple Adaptational Response ("MAR") Programs, as well as the Company's
most recent efforts to leverage its compounds and their unique mechanisms of
action in selected anti-inflammatory and neurodegenerative conditions
including multiple sclerosis.
A copy of the Paratek presentation will be available upon request.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc. is engaged in the discovery and
commercialization of new therapeutics that treat serious and life-threatening
diseases, with a particular focus on the growing worldwide problem of
antibiotic resistance. Paratek's lead programs are advancing novel compounds
that can circumvent or block bacterial resistance, as well as drugs that can
prevent infection by interfering with Multiple Adaptational Response ("MAR")
mechanisms in bacteria. Out of these efforts, Paratek has discovered a new
class of antibiotics, the aminomethylcyclines, that target the need for new
and potent antibacterials to overcome the problem of rapidly growing bacterial
resistance. The Company's lead antibiotic clinical candidate, BAY 73-7388,
the first product from this class, is being developed in a collaborative
partnership with Bayer HealthCare AG for the treatment of serious infections.
Outside the antibacterial therapeutic area, Paratek has also established
an internal effort to exploit its novel families of compounds and their unique
mechanism of action in selected anti-inflammatory and neurodegenerative
conditions. Paratek has an active chemical synthesis effort to produce novel
and diverse small molecules, with the goal of developing non-antibacterial
products with improved activity in serious diseases based upon a growing body
of clinical and basic research supporting this approach.
Paratek is privately held and headquartered in Boston, Massachusetts, USA.
For more information, visit Paratek's website at http://www.paratekpharm.com.
SOURCE Paratek Pharmaceuticals, Inc.